Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA - Takeaways - MDSpire

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA

  • By

  • Royston Ponraj

  • Adam Bryant

  • Lindsay Dunlop

  • Heather Range

  • Cherry Cobrador

  • Silvia Ling

  • Danny Hsu

  • July 26, 2023

  • 0 min

Share

  • 1

    Carfilzomib is an effective treatment for multiple myeloma but can cause thrombotic microangiopathy (TMA), leading to severe complications.

  • 2

    TMA from carfilzomib is characterized by microangiopathic hemolytic anemia (MAHA) and acute kidney injury, with a spectrum of severity.

  • 3

    In a study of 31 patients, 35.5% experienced MAHA, with two developing severe TMA, highlighting the risk associated with carfilzomib.

  • 4

    Episodes of low-grade MAHA were brief and often associated with transient acute kidney injury, indicating potential subclinical TMA.

  • 5

    Severe TMA cases showed significant renal impairment and complications, with one patient requiring eculizumab treatment for recovery.

Original Source(s)

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA

  • by Royston Ponraj, Adam Bryant, Lindsay Dunlop, Heather Range, Cherry Cobrador, Silvia Ling, Danny Hsu

  • July 26, 2023

Related Content

Differential expression of immune activation markers in T cells from patients with multiple myeloma

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research